TYK Medicines Inc (2410) fair value: what the stock is really worth
We calculate from audited financials what TYK Medicines Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch TYK Medicines Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
25‑month range HK$2.68 – HK$55.50 · fair‑value band HK$0.2550 – HK$0.5185 · the HK$2.99 price screens above the HK$0.3485 fair value. Dashed = 300-day average. As of Sep 13, 2026.
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products.
Show more
TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including breast cancer and prostate cancer; TY-2136b, an oral ROS proto-oncogene 1/neurotrophic tyrosine receptor kinase inhibitor for the treatment of solid tumors; TY-2699a, a selective CDK7 inhibitor for the treatment of advanced/metastatic solid tumors; and TY-0540, a selective CDK2/4/6 inhibitor to treat advanced/metastatic solid tumors. In addition, it develops TY-1054, an oral yes associated protein-transcriptional enhanced associate domain inhibitor for cancer treatment; CDK4, preclinical-stage oral CDK4 inhibitor for cancer treatment; TY-3002, a small-molecule, orally administered glucagon like peptide-1 receptor agonist (GLP-1RA) intended for the treatment of type 2 diabetes mellitus (T2DM) and obesity; and EGFR/FAK (PROTAC) and PI3Ka to treat solid tumors; and GLP-1 for the treatment of T2DM and overweight or obesity. The company was incorporated in 2017 and is headquartered in Huzhou, China.
Stock analysis
TYK Medicines Inc (2410) currently trades at HK$2.99, while our model-based Fair Value estimate is HK$0.3485, implying the stock looks roughly 756.2% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 82/100, which puts the evidence level at low.
Scenario range: HK$0.2550 (bear) to HK$0.5185 (bull), the price of HK$2.99 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
TYK Medicines Inc reported revenue of 0 CNY in FY2025 versus 44.2M CNY in FY2022. Reported net income was −292M CNY in FY2025.
Key figures
Market cap HK$2.4B (≈ $309M) · EPS (TTM) HK$−0.3000 · Return on equity −80.6% · Return on assets (EBIT) −41.7% · Revenue (TTM) HK$107K · Free cash flow −HK$255M · Net cash HK$215M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −88%, 2410 screens richer than that median.
Fair Value models
Bear HK$0.2550Fair Value HK$0.3485Bull HK$0.5185
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 645 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score32 · Bottom 25%
Profitability
Return on assets−24% · Below median
Net margin (TTM)0% · Below median
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is TYK Medicines Inc (2410) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of HK$0.3485 versus a price of HK$2.99, about −88% upside (overvalued).
What is the fair value of 2410?
Our model-based fair value for TYK Medicines Inc is HK$0.3485 (as of Sep 13, 2026), built from audited fundamentals. The current price: HK$2.99.
What is the quality score of 2410?
TYK Medicines Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TYK Medicines Inc (2410)?
Our model-based price target is the fair value of HK$0.3485 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario HK$0.2550, optimistic scenario HK$0.5185. It is a calculation from audited fundamentals, not an analyst target.
What is the TYK Medicines Inc stock forecast for 2026?
Our models put fair value at HK$0.3485, about −88% upside versus a price of HK$2.99 (overvalued). Cautious scenario HK$0.2550, optimistic scenario HK$0.5185. The calculation is refreshed regularly with new filings.
What is the revenue of TYK Medicines Inc (2410)?
TYK Medicines Inc reported trailing-twelve-month revenue of about HK$107K (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of TYK Medicines Inc (2410)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TYK Medicines Inc it is HK$0.3485 per share (as of Sep 13, 2026), against a price of HK$2.99. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is TYK Medicines Inc stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 2410 trades above its calculated fair value: price HK$2.99, fair value HK$0.3485, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2410?
No. The price is what the market pays today (HK$2.99); the fair value is what the company's own numbers justify (HK$0.3485). For TYK Medicines Inc the two are HK$2.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is TYK Medicines Inc worth?
The market values TYK Medicines Inc at about HK$2.4B (market capitalisation, as of Sep 13, 2026). Per share that is HK$2.99; our models calculate a fair value of HK$0.3485 per share.
What do the bullish and bearish scenarios say about 2410?
Our models span a range for TYK Medicines Inc: cautious scenario HK$0.2550, base HK$0.3485, optimistic HK$0.5185 per share (as of Sep 13, 2026, price HK$2.99). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TYK Medicines Inc (2410)?
Balance-sheet figures for TYK Medicines Inc (as of Sep 13, 2026): return on equity −80.6%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
Which stocks are comparable to TYK Medicines Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TYK Medicines Inc stock attractive at the current price?
The data as of Sep 13, 2026: price HK$2.99, calculated fair value HK$0.3485 (−88%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2410 calculated?
We run TYK Medicines Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.3485, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. TYK Medicines Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with TYK Medicines Inc right now?
The price sits above even our optimistic bull case (HK$0.5185). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.2550 to HK$0.5185) leaves room in how you read the outcome.
Key figures of TYK Medicines Inc
How large is the market capitalisation of TYK Medicines Inc (2410)?
The market capitalisation of TYK Medicines Inc is HK$2.4B (≈ $309M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of TYK Medicines Inc (2410)?
Earnings per share at TYK Medicines Inc are HK$−0.3000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of TYK Medicines Inc (2410)?
The return on equity (ROE) of TYK Medicines Inc is −80.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TYK Medicines Inc (2410)?
On an EBIT basis the return on assets of TYK Medicines Inc is −41.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does TYK Medicines Inc (2410) generate?
The free cash flow of TYK Medicines Inc is −HK$255M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does TYK Medicines Inc (2410) hold?
TYK Medicines Inc holds more cash than debt, HK$215M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch TYK Medicines Inc in the live analysis
One click puts TYK Medicines Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
